Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial

Table 1 Baseline demographic and clinical characteristics of the three patient groups

	Switch	ALD	Control	P value
Number of subjects	17	15	16
Male/female	1/16	1/14	4/11
Average age, years	65.8 ± 10.6	63.8 ± 9.3	64.8 ± 9.2	N.S.
Average BMI, kg/m²	21.9 ± 4.2	24.0 ± 2.6	24.6 ± 3.8	N.S.
JOA score	49.8 ± 9.7	53.3 ± 14.5	48.6 ± 11.0	N.S.
UCLA activity score	4.4 ± 1.2	5.0 ± 0.9	4.4 ± 1.4	N.S.
HHS	56.9 ± 9.9	54.7 ± 12.5	49.2 ± 10.6	N.S.
Lumbar spine BMD, g/cm²	0.8 ± 0.2	0.9 ± 0.1	0.9 ± 0.1	N.S.

ISSN: 1749-799X